Expression of PARP-1 in Multiple Sclerosis Patients

April 29, 2025 updated by: Elshimaa A.Mateen, Sohag University

Expression of PARP-1 in Optic Neuritis of Multiple Sclerosis Patients

This study will explore the expression of PARP-1 in optic neuritis of multiple sclerosis patients.

The data will be collected from Sohag University hospital in the period from the start of August 2021 to the end of December 2021.

The study protocol will be approved by the Scientific Research Ethical Committee, Faculty of Medicine, Sohag University.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt, 82511
        • Elshimaa A.Mateen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients with multiple sclerosis with or without optic neuritis Multiple sclerosis will be diagnosed according to the McDonald criteria

Exclusion Criteria:

  • • Isolated optic neuritis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control group
Genetic: Blood sampling
Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
Active Comparator: MS with optic neuritis
Genetic: Blood sampling
Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
Active Comparator: Ms without optic neuritis
Genetic: Blood sampling
Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measure PARP-1 mRNA
Time Frame: 2 weeks
measure PARP-1 mRNA
2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optic nerve, RNFL and GCC layer affection by MS
Time Frame: 2 weeks

Optic nerve Retinal nerve fibre layer (RNFL) in um

) and Ganglion cell complex (GCC) layer affection in um by MS in correlation to PARP-1 mRNA
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2021

Primary Completion (Actual)

March 30, 2022

Study Completion (Actual)

April 30, 2022

Study Registration Dates

First Submitted

December 7, 2021

First Submitted That Met QC Criteria

January 18, 2022

First Posted (Actual)

January 19, 2022

Study Record Updates

Last Update Posted (Actual)

May 2, 2025

Last Update Submitted That Met QC Criteria

April 29, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-05-12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe